EGFR and metastatic colorectal cancer: Retrospective data demonstrating a lack of response of patients with KRAS exon 2 mutant, and now extended RAS mutant, metastatic colorectal cancer to anti-EGFR therapy has changed the focus of colorectal cancer treatment to one of personalized cancer care.